VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 12, 2013) - Pyng Medical Corp. (TSX VENTURE:PYT) (the "Company") today announced that it recently submitted its next generation Intraosseous Infusion device for review by the Food and Drug Administration (FDA - United States). This robust and easy-to-use device builds upon the features of the Company's leading FAST1® Intraosseous Infusion System, and the company will market and sell the new product once approved to do so by FDA.

The Company today also announced a new technology partnership with AccuMED Innovative Technologies of Buffalo, New York (USA). AccuMED's business model is to utilize its capabilities in engineering design, materials and advanced manufacturing techniques to develop and manufacture customized Medical Devices with its partners, and this is being leveraged by the Company to bring new and improved products to market within its Trauma market segment. The Company currently sells the award-winning MAT® Tourniquet and the leading T-POD® Pelvic Stabilization Device into the Trauma segment, and expects to be adding to this portfolio via the AccuMED partnership.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

More information about the Company is available on SEDAR at [ www.sedar.com ] under the Company's profile and on its website: [ www.pyng.com ].

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Contributing Sources

---

Market Wire